Asset
BRENSOCATIB
Insmed Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05673603 | phase1 | completed | 2021-07-20 | 2023-02-14 | Insmed Incorporated | A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment |
| NCT06685835 | phase2 | terminated | 2024-12-16 | 2026-02-12 | Insmed Incorporated | A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT06013241 | phase2 | completed | 2023-10-30 | 2025-09-30 | Insmed Incorporated | A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) |
| NCT06178783 | phase1 | completed | 2023-12-27 | 2024-01-04 | Insmed Incorporated | A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants |
| NCT05927597 | phase1 | completed | 2019-01-09 | 2019-08-01 | Insmed Incorporated | A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 217673 | NDA | INSMED INC |
Marketed products (2)
- BRINSUPRI
- BRINSUPRI